Secondary hyperparathyroidism considerations

Authors

  • Alex Ramón Valencia Herrera
  • Liliana Katherine Sailema López
  • Génesis Alexandra Zúñiga Cárdenas
  • David Alejandro Andrade Hurtado

Keywords:

Hyperparathyroidism, chronic kidney disease, metabolism, parathyroid glands, parathyroid hormone levels

Abstract

Introduction: Secondary hyperparathyroidism is a common endocrine disease in patients with chronic kidney disease.
Objective: To analize secondary hyperparathyroidism.
Methods: The study was exploratory, observational, cross-sectional, and retrospective. The search was performed in SCOPUS and Web of Science databases, and included articles published between 2018 and 2023 that dealt with secondary hyperparathyroidism.
Results: Among the results obtained, it is evident that the classification of secondary hyperparathyroidism based on parathyroid hormone level can help identify patients who are at higher risk of developing complications related to kidney disease. The relationship between lithium treatment and secondary hyperparathyroidism was obtained, highlighting the need for adequate follow-up of patients receiving this drug. The relationship between obesity and secondary hyperparathyroidism was also evidenced.
Conclusions: It is concluded that secondary hyperparathyroidism is a condition in which the parathyroid glands produce too much parathyroid hormone in response to a chronic decrease in blood calcium levels. Furthermore, that the treatment of secondary hyperparathyroidism in patients with chronic kidney disease is based in many cases on the correction of hypocalcemia and hypovitaminosis D, and on the reduction of parathyroid hormone levels, as well as that patients may require pharmacological therapy, such as vitamin D supplements and calcimimetics, or parathyroid surgery.

Downloads

Download data is not yet available.

Published

2023-07-02

How to Cite

1.
Valencia Herrera AR, Sailema López LK, Zúñiga Cárdenas GA, Andrade Hurtado DA. Secondary hyperparathyroidism considerations. Rev Cubana Inv Bioméd [Internet]. 2023 Jul. 2 [cited 2025 Aug. 1];42(2). Available from: https://revibiomedica.sld.cu/index.php/ibi/article/view/2887